Average Bioequivalence (ABE) for FDA: SAS Code, Data, Output and Interpretation

A step-by-step worked example of the FDA average bioequivalence analysis for a 2x2 crossover study: the statistical concepts, a dummy dataset, annotated SAS code with PROC GLM, the output and how to interpret the 90% confidence interval.

Average bioequivalence (ABE) is the standard method the US FDA uses to decide whether a generic (test) product delivers the same rate and extent of absorption as the reference product. For most drugs it is assessed in a two-treatment, two-period, two-sequence (2×2) crossover study, and the conclusion rests on one result: the 90% confidence interval for the test/reference geometric mean ratio must lie within 80.00–125.00%.

This article walks through the complete analysis on a dummy dataset: the statistical concepts behind the model, the SAS code, the output, and the interpretation of each number that matters for the decision.

What the FDA requires

  • Parameters. Cmax, AUC0-t and AUC0-inf, each analysed separately after natural-log transformation.
  • Model. Analysis of variance with sequence, subject nested within sequence, period and treatment.
  • Criterion. The 90% confidence interval of the geometric mean ratio (test/reference) must fall entirely within 80.00–125.00% for every parameter.
  • No rounding in your favour. The limits are applied to the interval reported to two decimal places. A lower limit of 79.99% fails.

Statistical concepts behind the model

1. Log-normal data and the log transformation

Cmax and AUC are positive, right-skewed and behave multiplicatively, so they are assumed to follow a log-normal distribution. After taking natural logs the data are approximately normal with stable variance, and a difference of log means corresponds to a ratio of geometric means. Every estimate is therefore calculated on the log scale and exponentiated at the end.

2. The 2×2 crossover model

Each log-transformed observation is modelled as:

Y = overall mean + sequence + subject(sequence) + period + treatment + residual error
TermWhat it accounts for
SequenceDifferences between the group dosed TR and the group dosed RT (also where unequal carryover would show)
Subject(sequence)Differences between subjects; this removes between-subject variability from the treatment comparison
PeriodSystematic differences between period 1 and period 2 (for example assay drift or study conduct)
TreatmentThe test-versus-reference difference: the quantity of interest
Residual errorWithin-subject variability, used to build the confidence interval

3. Each subject is their own control

Because every subject receives both products, the comparison is made within subjects. Between-subject variability, which is usually much larger than within-subject variability, drops out. This is why a crossover study needs far fewer subjects than a parallel-group study.

4. Why the limits are 80.00–125.00%

The limits look asymmetric on the original scale but are symmetric on the log scale: ln(0.80) = −0.2231 and ln(1.25) = +0.2231. A 20% decrease and a 25% increase are the same distance from a ratio of 1 once the data are log-transformed.

5. Two one-sided tests (TOST) and the 90% confidence interval

Bioequivalence reverses the usual logic of hypothesis testing. The null hypothesis is that the products are not equivalent (the ratio is below 80% or above 125%), and the study must reject it. Schuirmann's procedure does this with two one-sided t-tests, each at the 5% level. Rejecting both is mathematically identical to the 90% confidence interval lying inside the limits, which is why a 90% interval, not a 95% interval, is reported.

6. Standard error of the treatment difference

In a 2×2 crossover the standard error of the difference is √(MSE/2 × (1/n1 + 1/n2)), where MSE is the residual mean square and n1, n2 are the number of subjects in each sequence. The confidence interval uses the t distribution with the residual degrees of freedom (N − 2).

7. Type III sums of squares and the sequence test

Type III sums of squares test each effect adjusted for all the others, which gives valid results when the sequences are unbalanced. The sequence effect is a between-subject effect, so it must be tested against the subject(sequence) mean square, not the residual. This is the purpose of the TEST statement in the code. By convention it is assessed at the 10% level.

8. Least-squares means and geometric means

Least-squares means are treatment means adjusted for the other terms in the model. Exponentiating an LS mean on the log scale gives the geometric LS mean, and exponentiating the difference between the two LS means gives the geometric mean ratio.

9. Intra-subject CV

The residual mean square estimates the within-subject variance on the log scale. It converts to a coefficient of variation with CV = 100 × √(exp(MSE) − 1). This value drives the width of the confidence interval and is the main input for sample size calculation in future studies.

10. Statistical significance is not the same as inequivalence

The p-value for treatment tests whether the ratio differs from exactly 100%. Bioequivalence asks a different question: whether the ratio is close enough to 100%. A precise study can show a statistically significant treatment effect and still be bioequivalent. The example below shows exactly this for Cmax.

Study design and dummy data

The example is a single-dose, randomised, two-treatment, two-period, two-sequence crossover study in 24 healthy subjects, 12 per sequence (TR and RT). The values are simulated and are for illustration only. Cmax is in ng/mL and AUC0-t in ng·h/mL. The suffix 1 or 2 is the period.

data pk;
   input subj seq $ cmax1 cmax2 auct1 auct2;
   datalines;
01 TR   446.4   540.0   4319   4474
02 RT   380.0   303.7   2724   3759
03 TR   314.6   286.5   2668   2699
04 RT   397.3   439.9   3467   4000
05 TR   307.1   325.9   1729   2268
06 RT   487.0   333.0   2773   3182
07 TR   294.0   503.1   3460   3703
08 RT   423.1   496.2   3569   3304
09 TR   579.5   775.6   6291   5030
10 RT   529.5   380.4   4757   3972
11 TR   359.2   576.6   3232   3932
12 RT   585.4   533.0   4610   3835
13 TR   469.6   515.9   4854   6239
14 RT   362.4   392.9   4740   4700
15 TR   523.5   536.4   5048   3367
16 RT   265.4   182.5   2358   2404
17 TR   342.2   388.7   3846   3940
18 RT   356.4   391.1   3413   3187
19 TR   341.5   364.1   4288   4311
20 RT   558.6   479.8   4019   3950
21 TR   475.3   528.6   4986   4789
22 RT   288.9   267.3   3120   2360
23 TR   542.1   475.4   4473   4588
24 RT   370.6   494.0   5571   6000
;
run;

SAS code, step by step

Step 1: Restructure to one record per subject and period

The treatment received in each period is read from the sequence code, and both parameters are log-transformed.

data pklong;
   set pk;
   length trt $1;
   array c{2} cmax1 cmax2;
   array a{2} auct1 auct2;

   do per = 1 to 2;
      trt    = substr(seq, per, 1);   /* T or R                 */
      cmax   = c{per};
      auct   = a{per};
      lncmax = log(cmax);             /* natural log            */
      lnauct = log(auct);
      output;
   end;

   keep subj seq per trt cmax auct lncmax lnauct;
run;

Step 2: Fit the ANOVA model with PROC GLM

Treatment levels sort alphabetically as R then T, so the coefficients -1 1 estimate test minus reference. CLPARM with ALPHA=0.10 returns the 90% confidence limits.

ods output OverallANOVA=anova Estimates=est LSMeans=lsm;

proc glm data=pklong;
   class seq subj per trt;
   model lncmax lnauct = seq subj(seq) per trt / ss3 clparm alpha=0.10;

   /* Sequence is tested against between-subject variation */
   test h=seq e=subj(seq) / htype=3 etype=3;

   lsmeans trt / stderr;
   estimate 'T vs R' trt -1 1;
run;
quit;

Step 3: Back-transform and apply the bioequivalence limits

data mse;
   set anova;
   where source = 'Error';
   mse = ms;
   keep dependent mse;
run;

proc sort data=est;  by dependent;  run;
proc sort data=mse;  by dependent;  run;

data abe;
   merge est mse;
   by dependent;

   ratio    = 100 * exp(estimate);          /* geometric mean ratio (%) */
   lower    = 100 * exp(lowercl);           /* 90% CI lower limit (%)   */
   upper    = 100 * exp(uppercl);           /* 90% CI upper limit (%)   */
   cv_intra = 100 * sqrt(exp(mse) - 1);     /* intra-subject CV (%)     */

   length conclusion $20;
   if round(lower, 0.01) ge 80.00 and round(upper, 0.01) le 125.00
      then conclusion = 'Bioequivalent';
      else conclusion = 'Not bioequivalent';
run;

proc print data=abe noobs;
   var dependent ratio lower upper cv_intra conclusion;
   format ratio lower upper cv_intra 8.2;
run;

Step 4: Geometric least-squares means

data geolsm;
   set lsm;
   geomean = exp(lsmean);
   keep dependent trt lsmean geomean;
run;

proc print data=geolsm noobs;
   format lsmean 10.6 geomean 10.2;
run;

Alternative: PROC MIXED when data are incomplete

With complete data, PROC GLM and PROC MIXED give the same estimate and confidence interval. When a subject is missing a period, PROC GLM effectively discards that subject for the treatment comparison, while PROC MIXED with subject as a random effect keeps the available observation. The method must be stated in the protocol in advance.

proc mixed data=pklong method=reml;
   class seq subj per trt;
   model lncmax = seq per trt / ddfm=kr;
   random subj(seq);
   lsmeans trt;
   estimate 'T vs R' trt -1 1 / cl alpha=0.10;
run;

Output

ANOVA for ln(Cmax)

SourceDFSum of squaresMean square
Model253.035011790.12140047
Error220.498957260.02267988
Corrected total473.53396905

R-square = 0.8588, Root MSE = 0.1506.

Type III tests for ln(Cmax)

SourceDFType III SSF valuePr > FError term
Sequence10.144115591.160.2928Subject(sequence)
Period10.014434320.640.4335Residual
Treatment10.146706526.470.0185Residual

Type III tests for ln(AUC0-t)

SourceDFType III SSF valuePr > FError term
Sequence10.084561410.570.4602Subject(sequence)
Period10.000208800.010.9096Residual
Treatment10.002378610.150.7021Residual

Residual mean square for ln(AUC0-t) = 0.01584409 with 22 degrees of freedom.

Estimate of test minus reference (log scale)

ParameterEstimateStandard errort valuePr > |t|90% lower90% upper
ln(Cmax)−0.110569180.04347401−2.540.0185−0.18522032−0.03591804
ln(AUC0-t)−0.014078960.03633649−0.390.7021−0.076473940.04831602

Final bioequivalence summary

ParameterGeometric LS mean, testGeometric LS mean, referenceRatio T/R (%)90% CI (%)Intra-subject CV (%)Conclusion
Cmax (ng/mL)390.22435.8489.5383.09 – 96.4715.15Bioequivalent
AUC0-t (ng·h/mL)3753.763806.9898.6092.64 – 104.9512.64Bioequivalent

Interpretation

  1. Cmax. The geometric mean ratio is 89.53% with a 90% confidence interval of 83.09–96.47%. The whole interval lies within 80.00–125.00%, so the test product is bioequivalent to the reference for rate of absorption.
  2. AUC0-t. The ratio is 98.60% with a 90% confidence interval of 92.64–104.95%, well inside the limits. The products are bioequivalent for extent of absorption.
  3. Sequence effect. The p-values are 0.2928 for Cmax and 0.4602 for AUC0-t, both above 0.10. There is no evidence of a sequence or unequal carryover effect.
  4. Period effect. The p-values are 0.4335 and 0.9096. There is no systematic difference between periods. A significant period effect would not invalidate the study, because period is adjusted for in the model.
  5. Intra-subject variability. The CV is 15.15% for Cmax and 12.64% for AUC0-t. Both are well below 30%, so the product is not highly variable and the conventional unscaled limits are the appropriate criterion.
  6. Overall conclusion. Both parameters meet the criterion, so the test product is bioequivalent to the reference product. In a real submission AUC0-inf must also pass.

A significant treatment effect that is still bioequivalent. For Cmax the treatment p-value is 0.0185, so the ratio is statistically different from 100%. The confidence interval even excludes 100%. This does not affect the conclusion: the interval is entirely within 80.00–125.00%, and that is the only criterion. The study is simply precise enough to detect a difference of about 10% that is not considered clinically relevant.

Checking the standard error by hand. For Cmax, √(0.02267988 / 2 × (1/12 + 1/12)) = 0.0435, which matches the SAS standard error. With t(0.95, 22) = 1.7171, the interval is −0.1106 ± 1.7171 × 0.0435, giving −0.1852 to −0.0359, and exponentiating gives 83.09–96.47%.

Practical points

  • Pre-specify the model. State the procedure (GLM or MIXED), the model terms and the handling of missing data in the protocol and statistical analysis plan.
  • Subject exclusions. Decide exclusions such as vomiting or pre-dose concentrations above 5% of Cmax before unblinding the analysis, using criteria written in the protocol.
  • Tmax. Tmax is not log-transformed and is not assessed with this model. It is summarised descriptively or compared with a non-parametric method when clinically relevant.
  • Highly variable drugs. If the within-subject CV of the reference is 30% or more, a replicate design with the reference-scaled approach may be more suitable. See Reference-Scaled Average Bioequivalence (RSABE) for FDA.
  • Narrow therapeutic index drugs. The FDA applies tighter, product-specific criteria. Always check the product-specific guidance.

References

  • US FDA. Statistical Approaches to Establishing Bioequivalence, Guidance for Industry. 2001.
  • US FDA. Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA, Draft Guidance for Industry.
  • Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. Journal of Pharmacokinetics and Biopharmaceutics. 1987;15(6):657–680.
  • Chow SC, Liu JP. Design and Analysis of Bioavailability and Bioequivalence Studies. 3rd edition. Chapman and Hall/CRC; 2008.

The dataset in this article is simulated and is provided for training purposes only.

Found this useful?Share it with your team or network.

Need help applying this to your study?

Our statisticians, programmers and quality specialists can review it with you.